Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - carglumic acid, quantity: 200 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; sodium stearylfumarate - carbaglu is indicated in treatment of,? hyperammonaemia due to n-acetylglutamate synthase primary deficiency,? hyperammonaemia due to organic acidaemias such as:,-hyperammonaemia due to isovaleric acidaemia -hyperammonaemia due to methylmalonic acidaemia -hyperammonaemia due to propionic acidaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - osilodrostat phosphate, quantity: 7.155 mg (equivalent: osilodrostat, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; titanium dioxide; hypromellose; croscarmellose sodium; macrogol 4000; iron oxide yellow; mannitol; colloidal anhydrous silica; microcrystalline cellulose - isturisa is indicated for the treatment of endogenous cushing?s syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - osilodrostat phosphate, quantity: 14.31 mg (equivalent: osilodrostat, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; iron oxide red; magnesium stearate; colloidal anhydrous silica; iron oxide yellow; macrogol 4000; titanium dioxide; iron oxide black; microcrystalline cellulose; mannitol; hypromellose; croscarmellose sodium - isturisa is indicated for the treatment of endogenous cushing?s syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - osilodrostat phosphate, quantity: 1.431 mg (equivalent: osilodrostat, qty 1 mg) - tablet, film coated - excipient ingredients: purified talc; hypromellose; colloidal anhydrous silica; croscarmellose sodium; mannitol; iron oxide yellow; iron oxide red; magnesium stearate; macrogol 4000; titanium dioxide; microcrystalline cellulose - isturisa is indicated for the treatment of endogenous cushing?s syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - mercaptamine (cysteamine), quantity: 3.8 mg/ml - eye drops, solution - excipient ingredients: carmellose sodium; benzalkonium chloride; disodium edetate; citric acid monohydrate; sodium hydroxide; hydrochloric acid; water for injections - cystadrops is indicated for the treatment of corneal cystine deposits in adults and children with cystinosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - 45156 - medicine administration kit, percutaneous, medicated, single-use - medicine administration kit for signifor lar for single use only

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - siltuximab, quantity: 400 mg - injection, powder for - excipient ingredients: polysorbate 80; sucrose; histidine - sylvant is indicated for the treatment of patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - siltuximab, quantity: 100 mg - injection, powder for - excipient ingredients: histidine; polysorbate 80; sucrose - sylvant is indicated for the treatment of patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

United States - English - NLM (National Library of Medicine)

recordati rare diseases, inc. - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - attention deficit disorder with hyperactivity: desoxyn tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of desoxyn. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine p

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - 65413 - subcutaneous/intramuscular injection set, medicated - medicine administration kit for signifor lar for single use only.